One-Dose malaria cure for kids? new trial begins
NCT ID NCT07052162
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a single dose of tafenoquine in 30 children in Papua New Guinea who have vivax malaria. The goal is to see how the drug moves through the body and if it is safe. Vivax malaria can come back because it hides in the liver, and this drug aims to clear it completely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tafenoquine
- What this could lead to
- If successful, this could provide a simpler, single-dose treatment option for vivax malaria in children, helping to prevent relapses.
- What could go wrong
- This is a small, early-phase study focused on drug levels and safety, not yet proving effectiveness. Side effects like low hemoglobin are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS OF TAFENOQUINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alexishafen Health Centre
RECRUITINGMadang, Madang Province, MP511, Papua New Guinea